

Claims

1. An antibody, comprising:

a light chain variable domain (VL domain) consisting of a sequence having at
5 least 80% identity to an amino acid sequence of SEQ ID NO: 7, 8, 15, or 16; and

a heavy chain variable domain (VH domain) consisting of a sequence having at
least 80% identity to an amino acid sequence of any one of SEQ ID NOs: 18 to 25.

2. The antibody of claim 1, wherein the antibody specifically binds to cluster
10 of differentiation 3 (CD3).

3. The antibody of claim 2, wherein the CD3 includes human-derived CD3
and monkey-derived CD3.

4. The antibody of claim 1, wherein the antibody specifically binds to T cells.
15

5. The antibody of claim 4, wherein the T cells include human-derived T cells
and monkey-derived T cells.

6. The antibody of claim 1, wherein the antibody is a humanized antibody.
20

7. A polynucleotide that encodes the light chain variable domain (VL domain)
and the heavy chain variable domain (VH domain) of the antibody of claim 1.

8. An expression vector comprising the polynucleotide of claim 7.

9. A host cell transformed with the expression vector of claim 8.

5 10. A method for producing an antibody that specifically binds to CD3,
comprising culturing the host cell of claim 9.

11. A pharmaceutical composition for use in preventing or treating cancer,
comprising the antibody of claim 1 or a fragment thereof.

10

12. The pharmaceutical composition of claim 11, wherein the cancer is
pancreatic cancer, liver cancer, gastric cancer, lung cancer, colorectal cancer, rectal
cancer, thyroid cancer, esophageal cancer, kidney cancer, bladder cancer, prostate
cancer, cervical cancer, breast cancer, blood cancer, skin cancer, epithelial cancer, brain
15 cancer, central nerve system cancer, or ovarian cancer.

13. The antibody of claim 1 for use in preventing or treating cancer.

14. A use of the antibody of claim 1 in the manufacture of a medicament for
20 preventing or treating cancer.